sellWeak cluster of 610b5-1 plan
Hohl Benjamin sold $178k of ELVN
CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc.. 6,250 shares at an average of $28.56, traded Oct 28, 2024, filed Oct 30, 2024.
Warning score
34Value
$178k
6,250 shares
Holdings after
0
-100% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-025779, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 28, 2024 | MOption exercise Common Stock10b5-1 | +6,250 | $2.48 | $16k | 6,250 | Oct 30, 2024 |
| Oct 28, 2024 | SOpen-market sale Common Stock10b5-1 | -5,600 | $28.49 | $160k | 650 | Oct 30, 2024 |
| Oct 28, 2024 | SOpen-market sale Common Stock10b5-1 | -650 | $29.11 | $19k | 0 | Oct 30, 2024 |
| Oct 28, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -6,250 | $0.00 | $0 | 173,806 | Oct 30, 2024 |
Related signals
Other insiders at Enliven Therapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 17Weak | sell10b5-1 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin CHIEF FINANCIAL OFFICER | $94k | 4,250 | |
| 18Weak | sell10b5-1 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin CHIEF FINANCIAL OFFICER | $131k | 5,250 | |
| 15Weak | sell 610b5-1 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise CHIEF MEDICAL OFFICER | $24k | 816 | |
| 16Weak | sell 610b5-1 | ELVN Enliven Therapeutics, Inc. | Heyman Richard A. director | $47k | 1,570 | |
| 22Weak | sell 610b5-1 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin CHIEF FINANCIAL OFFICER | $24k | 814 | |
| 25Weak | sell 610b5-1 | ELVN Enliven Therapeutics, Inc. | Kintz Samuel PRESIDENT AND CEO | $28k | 924 | |
| 15Weak | sell 610b5-1 | ELVN Enliven Therapeutics, Inc. | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | $25k | 847 | |
| 15Weak | sell 610b5-1 | ELVN Enliven Therapeutics, Inc. | Patel Anish CHIEF OPERATING OFFICER | $21k | 716 | |
| 16Weak | sell 610b5-1 | ELVN Enliven Therapeutics, Inc. | Heyman Richard A. director | $35k | 1,270 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.